stockrow
Friday 6 November 2026
Export LTRN’s income statement to Excel — free account
Lantern Pharma Inc.
LTRN Healthcare Biotechnology
- EPS
- −42.5%
- Free cash flow
- +25.3%
Quarter to June 2026, against a year earlier
0.53
0.00
0.00%
Follow LTRN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 2 | — | — | — | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (2) | (2) | (6) | (12) | (14) | (16) | (21) | (17) | (19) | +38.8% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (2) | (2) | (6) | (12) | (14) | (16) | (21) | (17) | (19) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (0.28) | (1.23) | (1.37) | (1.13) | (1.31) | (1.47) | (1.93) | (1.57) | (1.62) | +27.9% | ||||||
| Cash flow | — | — | (0.20) | (1.08) | (1.31) | (0.97) | (1.18) | (1.32) | (1.66) | (1.44) | (1.13) | +32.3% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (0.20) | (1.08) | (1.32) | (0.97) | (1.18) | (1.32) | (1.66) | (1.44) | (1.13) | +32.3% | ||||||
| Book value | — | — | (0.03) | 0.48 | 4.58 | 6.56 | 5.16 | 3.77 | 1.97 | 0.60 | (0.26) | n/m | ||||||
| Shares, m | — | — | 6 | 2 | 4 | 11 | 11 | 11 | 11 | 11 | 11 | +8.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (1) | (2) | (6) | (11) | (13) | (14) | (18) | (16) | (14) | +43.2% | |||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (18.3%) | ||||||
| Free cash flow | — | — | (1) | (2) | (6) | (11) | (13) | (14) | (18) | (16) | (14) | +43.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 0 | 1 | 20 | 70 | 56 | 41 | 21 | 6 | 4 | n/m | |||||
| Net debt | — | — | 0 | (1) | (19) | (71) | (56) | (41) | (24) | (10) | (7) | +56.2% | ||||||
| Shareholders’ equity | — | — | 0 | 1 | 20 | 72 | 56 | 41 | 21 | 7 | (3) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (767.63) | (257.99) | (54.22) | (26.22) | (21.48) | (31.15) | (60.04) | (93.53) | (143.36) | +674.1 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | (638.75) | (930.33) | (2,999.83) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | (479.49) | (661.82) | (57.25) | (27.09) | (22.35) | (32.93) | (66.93) | (123.51) | (400.91) | +356.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 6 | 15 | 16 | 23 | 21 | 24 | 16 | — | +17.8% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Lantern Pharma Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACTU Actuate Therapeutics, Inc. | $18.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| ICU SeaStar Medical Holding Corporation | $10.2M | — (loss-making) | — (loss-making) | +81.95% (above 0%: growing) | n/m | +0.43% (above 0%: growing) | 91.22% | (616.42%) | Compare |
| MBRX Moleculin Biotech, Inc. | $9.2M | 0.0× | — | — | n/m | −19.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.1M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LEXX Lexaria Bioscience Corp. | $8.8M | — (loss-making) | — (loss-making) | −89.12% (below 0%: shrinking) | n/m | +53.90% (above 0%: growing) | 100.00% | 0.00% | Compare |
| NKGN NKGen Biotech, Inc. | $8.8M | — (loss-making) | — | — | n/m | +28.68% (above 0%: growing) | 100.00% | 0.00% | Compare |
| LTRN Lantern Pharma Inc. | $7.9M | — (loss-making) | — | — | n/m | +25.31% (above 0%: growing) | 0.00% | 0.00% | |
| TOVX Theriva Biologics, Inc. | $7.7M | — (loss-making) | — | +33.08% (above 0%: growing) | n/m | +34.69% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MTVA MetaVia Inc. | $7.2M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $8.9M | — | — | +33.08% | — | +14.56% | 95.61% | 0.00% |
Pay and ownership Proxy statement filed 19 October 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 763.75k | 778.96k | 70.79 |
| 2024 | 1.09m | 1.02m | 74.53 |
Ownership
Directors and executive officers, together
8.78%
Armistice Capital Master Fund Ltd.
9.99%
Thomas A. Satterfield, Jr.
6.53%
Biological Mimetics, Inc.
5.65%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement